III non-small cell lung cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Diagnosed by pathology or cytology as non-small cell lung cancer; 2. Clinically diagnosed as IIIB or IIIC by imaging examination included chest enhanced CT, cranial MRI and PET-CT; 3. Surgical treatment is not available: the same center must be consulted by two senior thoracic surgeons. If the two physicians have different opinions, then the third senior thoracic surgeon should be consulted; 4. Aged 18-75 years; 5. KPS score > 70 points or PS score 0-2 points; 6. The patient was initially treated, and no other anti-tumor treatment was received before enrollment. There was no pleural invasion and pleural effusion, respiratory function compensation and heart, liver, kidney and other organs; 7. Biopsy pathological detection of genes should be tested in lung adenocarcinoma patients before enrollment, including EGFR, ALK receptor negative; 8. No history of chest radiotherapy; 9. Patients could understand the situation of this study and have signed an informed consent form.
Exclusion criteria
Exclusion criteria: 1. have malignant tumors of other organs at the same time or 1.5 times the upper limit of normal (ULN); 2.5 times as much aspartate aminotransferase (AST), alanine aminotransferase (ALT) > ULN; serum creatinine > 1.5 times the upper limit of normal, And creatinine clearance < 60 ml / min; 8. without legal capacity or legal capacity is restricted; 9. has other experimental drugs at the same time or is participating in other clinical trials; 10. with any other circumstances that the investigators consider to be unsuitable for participation in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3 year overall survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| local control rate;progression free survival; | — |
Countries
China
Contacts
Zhongshan Hospital, Fudan University